Published in Discov Med on July 01, 2010
The clinicopathological and gene expression patterns associated with ulceration of primary melanoma. Pigment Cell Melanoma Res (2014) 0.83
Established and Emerging Biomarkers in Cutaneous Malignant Melanoma. Healthcare (Basel) (2014) 0.75
Use of statins and the risk of death in patients with prostate cancer. J Clin Oncol (2013) 5.28
Identification of genes associated with head and neck carcinogenesis by cDNA microarray comparison between matched primary normal epithelial and squamous carcinoma cells. Oncogene (2002) 1.82
Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer (2002) 1.53
Imiquimod in the treatment of breast cancer skin metastasis. J Clin Oncol (2014) 1.51
The role of surrogate markers in the clinical development of antiretroviral therapy: a model for early evaluation of targeted cancer drugs. Cancer Invest (2004) 1.50
Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin Cancer Res (2003) 1.31
Connexin43 pseudogene is expressed in tumor cells and inhibits growth. Oncogene (2004) 1.17
Gap junctions and connexins as therapeutic targets in cancer. Expert Opin Ther Targets (2010) 1.13
Cul3 overexpression depletes Nrf2 in breast cancer and is associated with sensitivity to carcinogens, to oxidative stress, and to chemotherapy. Mol Cancer Ther (2009) 1.11
In the end what matters most? A review of clinical endpoints in advanced breast cancer. Oncologist (2011) 1.09
E6/E7 proteins of HPV type 16 and ErbB-2 cooperate to induce neoplastic transformation of primary normal oral epithelial cells. Oncogene (2004) 1.07
Biopsies: next-generation biospecimens for tailoring therapy. Nat Rev Clin Oncol (2013) 1.02
Multicentric pleomorphic xanthoastrocytoma in a patient with neurofibromatosis type 1. Case report and review of the literature. J Neurosurg (2005) 1.02
The biology behind prognostic factors of cutaneous melanoma. Curr Opin Oncol (2010) 1.01
Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer. Anticancer Drugs (2003) 1.00
A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol Oncol (2002) 0.99
Systemic cancer therapy: achievements and challenges that lie ahead. Front Pharmacol (2013) 0.98
Syntheses and potential anti-prostate cancer activities of ionone-based chalcones. Bioorg Med Chem Lett (2008) 0.98
Glutathione analogues in cancer treatment. Curr Oncol Rep (2004) 0.97
Characteristics of older newly diagnosed cancer patients refusing cancer treatments. Support Care Cancer (2010) 0.96
A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients. Clin Cancer Res (2003) 0.95
Putative chemopreventive molecules can increase Nrf2-regulated cell defense in some human cancer cell lines, resulting in resistance to common cytotoxic therapies. Cancer Chemother Pharmacol (2009) 0.95
Usefulness of frailty markers in the assessment of the health and functional status of older cancer patients referred for chemotherapy: a pilot study. J Gerontol A Biol Sci Med Sci (2008) 0.94
Connexin43 pseudogene in breast cancer cells offers a novel therapeutic target. Mol Cancer Ther (2009) 0.94
The flavonoid Casticin has multiple mechanisms of tumor cytotoxicity action. Cancer Lett (2006) 0.93
Medication problems in older, newly diagnosed cancer patients in Canada: How common are they? A prospective pilot study. Drugs Aging (2009) 0.92
Are frailty markers useful for predicting treatment toxicity and mortality in older newly diagnosed cancer patients? Results from a prospective pilot study. Crit Rev Oncol Hematol (2010) 0.92
The EphB2 tumor suppressor induces autophagic cell death via concomitant activation of the ERK1/2 and PI3K pathways. Cell Cycle (2010) 0.91
Unexpected induction of the human connexin 43 promoter by the ras signaling pathway is mediated by a novel putative promoter sequence. Mol Pharmacol (2003) 0.91
Glutathione and glutathione analogues; therapeutic potentials. Biochim Biophys Acta (2012) 0.90
Phase I/II trial of the safety and efficacy of AE-941 (Neovastat) in the treatment of non-small-cell lung cancer. Clin Lung Cancer (2003) 0.90
A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer. Invest New Drugs (2005) 0.89
A novel missense mutation in the gamma-glutamylcysteine synthetase catalytic subunit gene causes both decreased enzymatic activity and glutathione production. Blood (2003) 0.89
The fall rate of older community-dwelling cancer patients. Support Care Cancer (2012) 0.88
A systematic review of clinical studies on hereditary factors in pelvic organ prolapse. Int Urogynecol J (2012) 0.88
Identification and characterization of novel Nrf2 inducers designed to target the intervening region of Keap1. Chem Biol Drug Des (2010) 0.87
Barriers and facilitators of adherence to medical advice on skin self-examination during melanoma follow-up care. BMC Dermatol (2013) 0.87
Cdc25A-inhibitory properties and antineoplastic activity of bisperoxovanadium analogues. Mol Cancer Ther (2003) 0.86
Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies. Invest New Drugs (2005) 0.85
Oltipraz is a bifunctional inducer activating both phase I and phase II drug-metabolizing enzymes via the xenobiotic responsive element. Mol Pharmacol (2003) 0.85
Difficulties in decision making regarding chemotherapy for older cancer patients: A census of cancer physicians. Crit Rev Oncol Hematol (2010) 0.84
The impact of a multimedia informational intervention on psychosocial adjustment among individuals with newly diagnosed breast or prostate cancer: a feasibility study. Patient Educ Couns (2009) 0.84
Histology and imaging of soft tissue sarcomas. Eur J Radiol (2009) 0.83
Cyclin D1 is essential for neoplastic transformation induced by both E6/E7 and E6/E7/ErbB-2 cooperation in normal cells. Oncogene (2004) 0.82
Next-generation biobanking of metastases to enable multidimensional molecular profiling in personalized medicine. Mod Pathol (2013) 0.82
Epidemiology of extracutaneous melanoma in the Netherlands. Cancer Epidemiol Biomarkers Prev (2010) 0.81
Patient and work flow and costs associated with staff time and facility usage at a comprehensive cancer centre in Quebec, Canada--a time and motion study. BMC Health Serv Res (2012) 0.81
A histone deacetylation-dependent mechanism for transcriptional repression of the gap junction gene cx43 in prostate cancer cells. Prostate (2006) 0.80
Redefining cancer: a new paradigm for better and faster treatment innovation. J Popul Ther Clin Pharmacol (2014) 0.79
Making sense of intratumor genetic heterogeneity: altered frequency of androgen receptor CAG repeat length variants in breast cancer tissues. Hum Mutat (2013) 0.79
Ehd3, a regulator of vesicular trafficking, is silenced in gliomas and functions as a tumor suppressor by controlling cell cycle arrest and apoptosis. Carcinogenesis (2013) 0.79
A cell-based system to identify and characterize the molecular mechanism of drug-metabolizing enzyme (DME) modulators. Biochem Pharmacol (2004) 0.79
Participation of older newly-diagnosed cancer patients in an observational prospective pilot study: an example of recruitment and retention. BMC Cancer (2009) 0.79
Potential medication problems in older newly diagnosed cancer patients in Canada during cancer treatment: a prospective pilot cohort study. Drugs Aging (2010) 0.78
Chronic lymphedema due to morbid obesity: an exceptional cause of abdominal wall angiosarcoma. Virchows Arch (2008) 0.78
Bridging structural biology and genetics by computational methods: an investigation into how the R774C mutation in the AR gene can result in complete androgen insensitivity syndrome. Hum Mutat (2003) 0.78
Incidence of Epstein-Barr virus in Syrian women with breast cancer: A tissue microarray study. Hum Vaccin Immunother (2015) 0.78
Emerging drug discovery approaches for selective targeting of "precursor" metastatic breast cancer cells: highlights and perspectives. Am J Transl Res (2011) 0.78
Magnetotactic bacteria penetration into multicellular tumor spheroids for targeted therapy. Conf Proc IEEE Eng Med Biol Soc (2010) 0.78
An examination of how different mutations at arginine 855 of the androgen receptor result in different androgen insensitivity phenotypes. Mol Endocrinol (2004) 0.78
Novel use of the fluorescent dye 5-(and-6)-chloromethyl SNARF-1 acetate for the measurement of intracellular glutathione in leukemic cells and primary lymphocytes. Cytometry A (2007) 0.78
Anthracyclines. Cancer Chemother Biol Response Modif (2005) 0.77
Structure-based identification of novel human gamma-glutamylcysteine synthetase inhibitors. Mol Pharmacol (2007) 0.77
Nucleic acid quality preservation by an alcohol-based fixative: comparison with frozen tumors in a routine pathology setting. Diagn Mol Pathol (2011) 0.77
The glutathione system in alkylator resistance. Cancer Treat Res (2002) 0.77
Physician recruitment of patients to non-therapeutic oncology clinical trials: ethics revisited. Front Pharmacol (2013) 0.77
TLK-199 (Telik). IDrugs (2005) 0.76
New frontiers in therapeutic resistance in cancer. Expert Rev Anticancer Ther (2012) 0.76
The dual role of the X-linked FoxP3 gene in human cancers. Mol Oncol (2011) 0.76
Collagen type III alpha 1 polymorphism (rs1800255, COL3A1 2209 G>A) assessed with high-resolution melting analysis is not associated with pelvic organ prolapse in the Dutch population. Int Urogynecol J (2014) 0.76
Advances in the approach to novel drug clinical development for breast cancer. Expert Opin Drug Discov (2014) 0.76
Post-transcriptional regulation of connexin43 in H-Ras-transformed cells. PLoS One (2013) 0.76
Dotlike or Golgi-like KIT and PDGFRA Staining in GISTs. Am J Surg Pathol (2009) 0.76
Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma. Medicine (Baltimore) (2017) 0.75
Plaque-Like Myofibroblastic Tumor: Report of 4 Cases. Am J Dermatopathol (2017) 0.75
Phase I study of nonpegylated liposomal doxorubicin plus trastuzumab in patients with HER2-positive breast cancer. Clin Breast Cancer (2009) 0.75
Design and syntheses of putative bioactive taxanes. Bioorg Med Chem (2002) 0.75
Umbilical polyp in an infant. Pediatr Dev Pathol (2007) 0.75
[The réseau de recherche sur le cancer: favoring a multi-disciplinary approach]. Bull Cancer (2006) 0.75
The nonapoptotic pathway mediating thymidine kinase/ganciclovir toxicity is reduced by signal from adenovirus type 5 early region 4. Mol Ther (2002) 0.75